<DOC>
	<DOCNO>NCT00620061</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety efficacy lubiprostone administration patient OBD .</brief_summary>
	<brief_title>Opioid-induced Bowel Dysfunction : Long-Term Assessment Lubiprostone</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Patient complete 12 week blind treatment SPI/0211OBD0631 SPI/0211OBD0632 study . Patient continue treat consistently chronic , noncancerrelated pain full agonist opiate continue opiate therapy duration study . Patient must willing continue abstain use disallow medication define per protocol . Patient newly diagnose impaired renal function identify Screening Visit ( i.e. , serum creatinine concentration &gt; 1.8 mg/dL ) . Patient experience unexplained and/or clinically significant weight loss define &gt; 5 % within 90 day prior Screening Visit . Patient plan participate another trial investigational drug device course extension study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>